BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Recruiting · NCT04162353 · Registry updated 2025-09-16Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 1 | 2025-09-16 | NCT04162353 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| iCAR Bio Therapeutics Ltd. | 2 |
| iCell Gene Therapeutics | 7 |
| Peking University Shenzhen Hospital | 48 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Chengdu Military General Hospital | Chengdu | China | 1 |
| Peking University Shenzhen Hospital, China | Shenzhen | China | 1 |